



Contact:

David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020

**Milestone Scientific Appoints Pharmaceutical Industry Executive
Lidong Zhang to Global Advisory Board**

LIVINGSTON, NJ, March 8, 2016 -- Milestone Scientific Inc. (NYSE: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced the appointment of Lidong Zhang to the company's Global Advisory Board, where he will aid in developing global partnerships and distribution channels for the company's medical and dental instruments.

Mr. Zhang brings nearly 30 years of senior pharmaceutical and healthcare experience, including relevant experience in R&D, sales, senior management and other positions in both domestic and multi-national pharmaceutical companies. These companies include large medical equipment manufacturers, pharmaceutical companies, biological product companies, medical information companies, and medical device companies. Mr. Zhang currently serves as CEO of Milestone China, a joint venture distribution company with Milestone Scientific, which supplies and distributes dental instruments and disposables to China. Prior to joining Milestone China, Mr. Zhang held senior executive positions with leading healthcare distribution companies in China, including President of China National Medicines Corporation, Ltd. (CNMC), President of China National Pharmaceutical Logistics Co. Ltd, and Vice President of China National Bio-tech Group. He also served as Chairman of National Medicines Prospect Dentech (Beijing) Co. Ltd. He brings extensive sales and distribution experience having led sales teams in excess of two thousand people. He also brings capital markets experience including involvement in the IPOs of China National Pharmaceutical Group (Sinopharm), the largest pharmaceutical company in China, and China National Medicines Corporation. He also oversaw the integration of China National Biological Group (CNBG) from six state-owned companies.

Leonard Osser, CEO of Milestone Scientific commented, "Mr. Zhang will be a valuable addition to our Global Advisory Board as we enter the final stages of our U.S. clinical trials for the epidural instrument. He brings extensive international experience and relationships that will aid in global distribution of our epidural and intra-articular instruments following regulatory marketing clearance. He also brings unique insight into product demand and strategy in foreign markets, which will be beneficial as we advance additional instruments already under development and strategize our product pipeline for the coming years."

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2014. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

###